European Medicines Agency (EMA) commentary on EMA/CHMP Guideline on allergen products development for immunotherapy and allergy diagnosis in moderate to low‐sized study populations

Documenti analoghi

• Evidence generation throughout paediatric medicines life cycle: findings from collaborative work between European Medicines Agency (EMA) and EUnetHTA on use of extrapolation
  di: Dominik Karres, et al.
  Pubblicazione: (2024)
• Novel drugs approved by the EMA, the FDA and the MHRA in 2024: A year in review
  di: Stavros Topouzis, et al.
  Pubblicazione: (2025)
• Performance of the accelerated assessment of the European Medicines Agency
  di: Vittorio Del Grosso, et al.
  Pubblicazione: (2025)
• Spotlight commentary: De‐labelling the truth: Clearing the fog around antibiotic allergy labels
  di: Iva Mikulić, et al.
  Pubblicazione: (2025)
• European Medicines Agency seeks stakeholders' views on its reflection paper on patient experience data
  di: Rosa Gonzalez‐Quevedo, et al.
  Pubblicazione: (2025)